Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage

Table 3 Management of women by histopathologic diagnosis

Histopathologic diagnosis		Management					Row total
		No treatment indicated (row%) (column%)	Immediate management based on colposcopic impression (row%) (column%)		Delayed excisional treatment on a recall visit (row%) (column%)
		No treatment indicated (row%) (column%)	With ablation	With LLETZ	Completed	Pending^a
<CIN2		1158 (88.7%) (100.0%)	90 (6.9%) (78.9%)	54 (4.1%) (69.2%)	3^c (0.2%) (12.0%)	0	1305 (100%)
CIN2	Diagnosed on biopsy/LLETZ	0	10 (40.0%) (8.8%)	11 (44.0%) (14.1%)	2 (8.0%) (8.0%)	2 (8.0%) (16.7%)	25 (100%)
CIN2	Diagnosed on ECC	0	0	0	8 (66.7%) (32.0%)	4 (33.3%) (33.3%)	12 (100%)
CIN3	Diagnosed on biopsy/LLETZ	0	13 (38.2%) (11.4%)	12 (35.3%) (15.4%)	5 (14.7%) (20.0%)	4 (11.8%) (33.3%)	34 (100%)
CIN3	Diagnosed on ECC^b	0	1 (16.7%) (0.9%)	0	3 (50.0%) (12.0%)	2 (33.3%) (16.7%)	6 (100%)
Cancer	Diagnosed on biopsy/LLETZ	0	0	1^d (20.0%) (1.3%)	4 (80.0%) (16.0%)	0	5 (100%)
Column total		1158 (100%)	114 (100%)	78 (100%)	25 (100%)	12 (100%)	Grand total = 1387

^aRecall attempts are temporarily paused due to COVID-19 pandemic spread
^bIncludes two women with OncoE6 HPV 16 positive, in whom LLETZ was recommended on recall and is still incomplete
^cIncludes one case with colposcopic impression of cancer treated with hysterectomy of what eventually turned out to be <CIN2; other two cases were recalled for LLETZ due to reporting error
^dInvasive squamous cell carcinoma with CIN3 at margins was diagnosed on on-site LLETZ leading to a recall for a repeat LLETZ with CIN3 diagnosis leading to a 2nd recall for a hysterectomy

ISSN: 1750-9378